Gary Abromovitz

Keine laufenden Positionen mehr

81 Jahre

Consumer Durables

Commercial Services

Aktive Beziehungen

Name	Geschlecht	Alter	Unternehmensverbindungen	Zusammenarbeit
Vincent Carson	M	64	HELEN OF TROY LIMITED	23 Jahre
Timothy Meeker	M	77	HELEN OF TROY LIMITED	20 Jahre
Thurman Case	M	67	HELEN OF TROY LIMITED	7 Jahre
Darren Woody	M	64	HELEN OF TROY LIMITED	20 Jahre
Beryl Raff	F	73	HELEN OF TROY LIMITED	10 Jahre
Krista Berry	F	59	HELEN OF TROY LIMITED	7 Jahre
Tessa Judge	F	40	HELEN OF TROY LIMITED	9 Jahre
Tabata Gomez	M	43	HELEN OF TROY LIMITED	2 Jahre
Elena Otero	F	59	HELEN OF TROY LIMITED	2 Jahre
Noel Geoffroy	F	52	HELEN OF TROY LIMITED	2 Jahre

Mehr sehen

Beziehungs-Chart

Beziehungen zu mehreren Unternehmen

Ehemalige Beziehungen

Name	Geschlecht	Alter	Unternehmensverbindungen	Zusammenarbeit
Gerald J. Rubin	M	80	HELEN OF TROY LIMITED	46 Jahre
Robert D. Spear	M	-	HELEN OF TROY LIMITED	-
Julien Mininberg	M	59	HELEN OF TROY LIMITED	10 Jahre
Michael Cafaro	M	-	HELEN OF TROY LIMITED	-
John R. Boomer	M	62	HELEN OF TROY LIMITED	-
Matthew Osberg	M	48	HELEN OF TROY LIMITED	7 Jahre
Thomas J. Benson	M	67	HELEN OF TROY LIMITED	13 Jahre
Thomas J. Stegmann	M	77	Venturis Therapeutics, Inc. Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX.	11 Jahre
Brian Grass	M	54	HELEN OF TROY LIMITED	15 Jahre
John B. Butterworth	M	72	HELEN OF TROY LIMITED	-
William F. Susetka	M	70	HELEN OF TROY LIMITED	11 Jahre
Stanlee N. Rubin	F	80	HELEN OF TROY LIMITED	43 Jahre
Richard J. Oppenheim	M	-	HELEN OF TROY LIMITED	-
Alexander Davern	M	57	HELEN OF TROY LIMITED	-
Adolpho R. Telles	M	74	HELEN OF TROY LIMITED	-
Daniel C. Montano	M	75	HELEN OF TROY LIMITED	23 Jahre
Leah Bailey	F	68	HELEN OF TROY LIMITED	2 Jahre
Robert Ballard	M	-	HELEN OF TROY LIMITED	2 Jahre
Connie Hallquist	F	-	HELEN OF TROY LIMITED	-
Frédéric M. Chanson	M	69	Venturis Therapeutics, Inc. Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX.	-
Pedro T. Contreras	M	-	HELEN OF TROY LIMITED	-
James C. Swaim	M	71	HELEN OF TROY LIMITED	1 Jahre
Bart Plaumann	M	-	HELEN OF TROY LIMITED	-
Christopher Carameros	M	70	HELEN OF TROY LIMITED	13 Jahre
John H. Conklin	M	-	HELEN OF TROY LIMITED	4 Jahre
Mike Norris	M	-	Venturis Therapeutics, Inc. Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX.	-
Alexander Gene Montano	M	-	Venturis Therapeutics, Inc. Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX.	-
Robert Levin	M	92	Venturis Therapeutics, Inc. Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX.	-
Thomas L. Ingram	M	69	Venturis Therapeutics, Inc. Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX.	-
Richard R. Dwyer	M	-	HELEN OF TROY LIMITED	-
Byron H. Rubin	M	74	HELEN OF TROY LIMITED	29 Jahre
Joong-Ki Baik	M	69	Venturis Therapeutics, Inc. Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX.	9 Jahre

Statistik

Land	Beziehungen	% des Gesamten
Bermuda	35	83,33%
Vereinigte Staaten	7	16,67%

Alter der Beziehungen

Aktive

Vergangene

Herr

Frau

Aufsichtsräte

Führungskräfte

Ursprung der Beziehungen

Börse
Insiders
Gary Abromovitz
Persönliches Netzwerk